EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to

Sandy Van Hemelryck iD, Erika Van Landuyt, Veerle Hufkens, Simon Vanveggel

Antiviral Therapy · 2024

DOI: 10.1177/13596535241248282 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antiviral Therapy, 2024. Verfasst von Sandy Van Hemelryck und 3 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceuticals NV, Beerse, Belgium. Hauptthemen laut MEDLINE: HIV Infections, Cobicistat, Emtricitabine, Tablets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) was developed as a once-daily, complete antiretroviral (ARV) regimen therapy to address the need for simplified protease inhibitor-based ARV regimens. This study assessed the swallowability and acceptability for long-term use of scored placebo tablets matching the D/C/F/TAF FDC tablets in children living with HIV-1.

Methods

This study (NCT04006704) was a Phase 1, open-label, randomized, single-dose, 2-period, 2-sequence crossover study in children living with HIV-1, aged ≥6 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsCobicistatEmtricitabineTabletsHIV-1Anti-HIV AgentsTenofovirDarunavirDrug CombinationsHumansMaleFemaleChildAlanineCross-Over StudiesDeglutitionAdenine

Stichwörter der Autor:innen

D/C/F/TAFHIVacceptabilityantiretroviral therapyfixed-dose combination therapyswallowability

Substanzen

CobicistatEmtricitabineTabletsAnti-HIV AgentsTenofovirDarunavirDrug Combinationstenofovir alafenamideAlanineAdenine

Autor:innen und Institutionen

  • Janssen Pharmaceuticals NV, Beerse, Belgium.

ORCID-Profile: Sandy Van Hemelryck

Förderung

  • Janssen Research and Development

Zitieren

APA

Van Hemelryck, S., Van Landuyt, E., Hufkens, V., & Vanveggel, S. (2024). Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to. Antiviral Therapy. https://doi.org/10.1177/13596535241248282

Vancouver

Van Hemelryck S, Van Landuyt E, Hufkens V, Vanveggel S. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to. Antiviral Therapy. 2024. doi:10.1177/13596535241248282

BibTeX
@article{VanHemelryck2024,
  author = {Van Hemelryck, Sandy and Van Landuyt, Erika and Hufkens, Veerle and Vanveggel, Simon},
  title = {Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to},
  journal = {Antiviral Therapy},
  year = {2024},
  doi = {10.1177/13596535241248282}
}
Kostenlos starten →